European Study Commences for Ancora Heart's AccuCinch Ventricular Repair System for Heart Failure Treatment
August 12, 2019—Ancora Heart, Inc. announced the first patient was enrolled in the CorCinch EU study. The study is a European multicenter clinical evaluation of the company's AccuCinch ventricular repair system as a treatment for patients with reduced ejection fraction systolic heart failure (HFrEF). The study will enroll up to 132 patients from heart centers across Europe.
The first patient was enrolled at Homolka Hospital in Prague, Czech Republic by Professor Petr Neužil, MD, Head of the Department of Cardiology at Homolka Hospital and Principal Investigator of the study. The AccuCinch procedure was completed by coinvestigator Vivek Reddy, MD, along with Prof. Neužil. Dr. Reddy is Director of Cardiac Arrhythmia Services at The Mount Sinai Hospital in New York, New York.
In the company's announcement, Prof. Neužil commented, "The transcatheter AccuCinch therapy is unique in its ventricular approach, which is intended to improve heart function by repairing the left ventricle for patients with systolic heart failure regardless of its origin. We are pleased to participate in this study because the AccuCinch has the potential to address the shortcomings of current medical, surgical, and transcatheter treatments and restore quality of life and longevity for this large patient population.”
According to Ancora Heart, this is the company's second recently initiated study evaluating the AccuCinch system focused specifically on heart failure and the enlarged left ventricle. Earlier this year, the company announced that the first patient was enrolled in a United States early feasibility study evaluating the AccuCinch system as a treatment for patients with HFrEF.
The transcatheter AccuCinch therapy is designed to complement and enhance the existing care to further manage symptoms and slow, or stop, the progression of heart failure. For some patients, AccuCinch may have the potential to reverse the enlargement of the left ventricle. For patients where heart failure has progressed beyond the ability for medications and pacemakers to manage symptoms, nonsurgical percutaneous device therapy with AccuCinch may provide an effective treatment option. The AccuCinch system is designed to directly repair the left ventricle of the heart, thereby addressing the fundamental issue in the progression of systolic heart failure, state Ancora Heart.
Sponsored by Cardiovascular Systems Inc.
Related Articles
Top 5 Articles From August 2019
State-of-the-art closure techniques for large-bore access.
By Amir Kaki, MD; and M. Chadi Alraies, MD
Mastering the ultrasound-guided access technique for cardiac and noncardiac interventions can reduce access-related complications and improve outcomes.
By Maarten P. van Wiechen, MD; and Nicolas M. Van Mieghem, MD, PhD, FACC, FESC
A guide to understanding intracardiac echocardiography for PFO closure, including available technologies, proper techniques, and potential benefits and limitations.
By Mohamad Alkhouli, MD
An overview of innovative preprocedural and intraprocedural imaging techniques, trial data, and current LAAO devices and devices in development.
By Saurabh Sanon, MD; and D. Scott Lim, MD
Discussing the design and function of radial artery compression technologies used for a safe closure of radial access after percutaneous cardiovascular intervention.
By Francesco Costa, MD, PhD, FESC; and Renato Scalise, MD
Top 5 from EVToday's Current Issue
Technical and procedural innovations in Y-90 radioembolization including existing and investigational next-generation technologies.
By Robert Abraham, MD, FRCPC, FSIR; Robert Lewandowski, MD, FSIR; Ripal T. Gandhi, MD, FSIR, FSVM; and David M. Liu, MD, FRCPC, FSIR
Considerations for choosing the right access equipment.
By Darren Klass, MBChB, MD, MRCS, FCRC, FRCPC; Anastasia Hadjivassiliou, MBBS, FRCR, FRCPC; and John Chung, MD, FRCPC
An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies.
By Ripal T. Gandhi, MD, FSIR, FSVM; Horacio Asbun, MD; Michael Chuong, MD; Filipe Kunzler, MD; and Govindarajan Narayanan, MD
Cases highlighting the potential for early benefit and improved quality of life and function associated with the use of FlowTriever and ClotTriever Systems in patients with cancer and VTE.
With Sirish A. Kishore, MD; and William C. Dillon, MD, FACC
Clinical and technical insights into treating hepatocellular carcinoma, cholangiocarcinoma, renal cell carcinoma, lung cancer, bone cancer, and in the palliative care setting.
By Siddharth A. Padia, MD; Theodore Bryan, MD; Rebecca Bennett, MD; Nadine Abi-Jaoudeh, MD, FSIR, CCRP; Raul N. Uppot, MD; Robert Suh, MD; Paul I. Mallinson, MBChB, FRCR, FRCPC; Peter L. Munk, MDCM, FRCPC, FSIR, FFRRCSI (Hon); Miyuki Sone, MD; and Yasuaki Arai, MD, FSIR, FCIRSE